Cite
HARVARD Citation
Cho, B. et al. (n.d.). 3100 Phase Ib/II study of the pan-cyclin-dependent kinase (CDK) inhibitor roniciclib (BAY 1000394) in combination with chemotherapy as first-line therapy in subjects with extensive disease small cell lung cancer (ED-SCLC). European journal of cancer. pp. S634-. [Online].